Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference

CARMIEL, Israel, Oct. 26, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Dror Bashan, President and Chief Executive Officer, is scheduled to present at the Stifel 2026 Healthcare Conference. The Conference is being held on November 10-12, 2026 at the Lotte New York Palace Hotel, New York City, NY.

Mr. Bashan will provide a live corporate overview on Tuesday, November 10, at 2:00 p.m. Eastern Time in the Hubbard Room, Fifth Floor, and the Company's management will participate in one-on-one meetings with registered investor attendees. Investors interested in arranging a meeting should contact their Stifel representative.

A live webcast of Mr. Bashan's presentation will be available at https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/5NTTgZrQJMJZ8iJS8xzFwq, and on the Events Calendar of the Investors section of the Company's website, www.protalix.com. An archived replay will be available following the event.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx^®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso^®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio^® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.

Investor Contact

Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
[email protected]

SOURCE Protalix BioTherapeutics, Inc.